D. E. Shaw & Co., Inc. Viridian Therapeutics, Inc.\De Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 442,070 shares of VRDN stock, worth $6.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

442,070

Previous 138,067 220.19%

Holding current value

$6.94 Million

Previous $3.14 Million 169.79%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$17.85 - $25.71 $5.43 Million - $7.82 Million	304,003 Added 220.19%	442,070 $8.47 Million
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $1.68 Million - $3.22 Million	138,067 New	138,067 $3.14 Million
Q4 2022 Feb 14, 2023	SELL	$18.78 - $29.74 $5.45 Million - $8.63 Million	-290,108 Reduced 46.18%	338,167 $9.88 Million
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $1.4 Million - $3.34 Million	-130,853 Reduced 17.24%	628,275 $12.9 Million
Q2 2022 Aug 15, 2022	SELL	$9.55 - $19.0 $228,884 - $455,373	-23,967 Reduced 3.06%	759,128 $8.78 Million
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $310,312 - $385,904	18,482 Added 2.42%	783,095 $14.5 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $689,898 - $947,784	44,083 Added 6.12%	764,613 $15.1 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $1,678 - $2,857	157 Added 0.02%	720,530 $11.9 Million
Q2 2021 Aug 16, 2021	BUY	$14.34 - $18.67 $7.63 Million - $9.93 Million	531,861 Added 282.14%	720,373 $13.2 Million
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $2.92 Million - $4.7 Million	188,512 New	188,512 $3.15 Million

Others Institutions Holding VRDN

# of Institutions

200

Shares Held

79.4M

Call Options Held

477K

Put Options Held

917K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $626M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account